What happens next in GLP-1 — and when.

Get the briefing

What moved in the GLP‑1 field, in your inbox.

@glp1briefing

Supply & discontinuations

Current entries in the FDA Drug Shortage Database for the molecules we track, including planned discontinuations.

9 presentations are currently in shortage and 5 flagged for discontinuation, listed by NDC because shortages are declared per package rather than per drug — one strength can be unavailable while another ships normally. This status has consequences beyond the pharmacy counter: while a drug is in shortage, compounders may legally prepare copies of it, and that permission narrows when the shortage lifts. The FDA revises these records in place, so the reason text you see is the current one rather than the original.

UpdatedDrugStatusPresentationCompanyFDA note
08/27/2026liraglutide
Injection
CurrentLiraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)
NDC 71288-563-85
Meitheal Pharmaceuticals, Inc.
08/27/2026liraglutide
Injection
CurrentLiraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)
NDC 71288-563-84
Meitheal Pharmaceuticals, Inc.
08/25/2026liraglutide
Injection
CurrentSaxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)
NDC 0169-2800-15
Novo Nordisk, Inc.Product will be available until discontinuation in January 2027
08/25/2026liraglutide
Injection
To Be DiscontinuedSaxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)
NDC 0169-2800-15
Novo Nordisk, Inc.Product will be available until discontinuation in January 2027; Discontinuation of the manufacture of the drug
08/25/2026liraglutide
Injection
CurrentLiraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)
NDC 0480-3667-20
Novo Nordisk, Inc.Distributed by Teva
08/25/2026liraglutide
Injection
CurrentLiraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)
NDC 0480-3667-22
Novo Nordisk, Inc.Distributed by Teva
08/25/2026liraglutide
Injection
CurrentVictoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)
NDC 0169-4060-13
Novo Nordisk, Inc.Estimated shortage duration: TBD
08/17/2026liraglutide
Injection
CurrentVictoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)
NDC 0169-4060-12
Novo Nordisk, Inc.Estimated shortage duration: TBD
08/13/2026liraglutide
Injection
CurrentLiraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)
NDC 0143-9144-02
Hikma Pharmaceuticals USA, Inc.
08/13/2026liraglutide
Injection
CurrentLiraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)
NDC 0143-9144-03
Hikma Pharmaceuticals USA, Inc.
06/04/2026semaglutide
Tablet
To Be DiscontinuedRybelsus, Tablet, 3 mg (NDC 0169-4303-30)
NDC 0169-4303-30
Novo Nordisk, Inc.Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.
06/04/2026semaglutide
Tablet
To Be DiscontinuedRybelsus, Tablet, 7 mg (NDC 0169-4307-30)
NDC 0169-4307-30
Novo Nordisk, Inc.Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.
06/04/2026semaglutide
Tablet
To Be DiscontinuedRybelsus, Tablet, 14 mg (NDC 0169-4314-30)
NDC 0169-4314-30
Novo Nordisk, Inc.Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.
05/14/2026liraglutide
Injection
To Be DiscontinuedLiraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46)
NDC 0480-7250-46
Teva Pharmaceuticals USA, Inc.Discontinuation of the manufacture of the drug